Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors

Michael J. Biles, Hiten D. Patel, Mohamad E. Allaf

Research output: Contribution to journalReview articlepeer-review

Abstract

The role for cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has evolved with advancements in systemic therapy. During the cytokine-based immunotherapy era, CN provided a clear survival benefit and was considered standard of care in management of mRCC. The development of targeted systemic therapy directed at the vascular endothelial growth factor pathway altered the treatment paradigm and accentuated the importance of risk stratification in treatment selection. This article reviews the literature evaluating the benefit of CN during the evolution of systemic therapy and provides clinical recommendations for current utilization of CN in patients with mRCC.

Original languageEnglish (US)
Pages (from-to)359-370
Number of pages12
JournalUrologic Clinics of North America
Volume47
Issue number3
DOIs
StatePublished - Aug 2020

Keywords

  • Cytoreductive nephrectomy
  • Kidney cancer
  • Renal cell carcinoma
  • Systemic therapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors'. Together they form a unique fingerprint.

Cite this